Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
537 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Obesity - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H2 2016, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape. Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 15, 16, 128, 33 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 46 and 14 molecules, respectively.Obesity. Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 Introduction 7 Obesity Overview 8 Therapeutics Development 9 Obesity - Therapeutics under Development by Companies 11 Obesity - Therapeutics under Investigation by Universities/Institutes 21 Obesity - Pipeline Products Glance 24 Obesity - Products under Development by Companies 28 Obesity - Products under Investigation by Universities/Institutes 40 Obesity - Companies Involved in Therapeutics Development 44 Obesity - Therapeutics Assessment 144 Drug Profiles 166 Obesity - Dormant Projects 468 Obesity - Discontinued Products 493 Obesity - Product Development Milestones 500 Appendix 509
List of Tables Number of Products under Development for Obesity, H2 2016 36 Number of Products under Development for Obesity - Comparative Analysis, H2 2016 37 Number of Products under Development by Companies, H2 2016 39 Number of Products under Development by Companies, H2 2016 (Contd..1) 40 Number of Products under Development by Companies, H2 2016 (Contd..2) 41 Number of Products under Development by Companies, H2 2016 (Contd..3) 42 Number of Products under Development by Companies, H2 2016 (Contd..4) 43 Number of Products under Development by Companies, H2 2016 (Contd..5) 44 Number of Products under Development by Companies, H2 2016 (Contd..6) 45 Number of Products under Development by Companies, H2 2016 (Contd..7) 46 Number of Products under Development by Companies, H2 2016 (Contd..8) 47 Number of Products under Investigation by Universities/Institutes, H2 2016 48 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 49 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 50 Comparative Analysis by Late Stage Development, H2 2016 51 Comparative Analysis by Clinical Stage Development, H2 2016 52 Comparative Analysis by Early Stage Development, H2 2016 53 Comparative Analysis by Unknown Stage Development, H2 2016 54 Products under Development by Companies, H2 2016 55 Products under Development by Companies, H2 2016 (Contd..1) 56 Products under Development by Companies, H2 2016 (Contd..2) 57 Products under Development by Companies, H2 2016 (Contd..3) 58 Products under Development by Companies, H2 2016 (Contd..4) 59 Products under Development by Companies, H2 2016 (Contd..5) 60 Products under Development by Companies, H2 2016 (Contd..6) 61 Products under Development by Companies, H2 2016 (Contd..7) 62 Products under Development by Companies, H2 2016 (Contd..8) 63 Products under Development by Companies, H2 2016 (Contd..9) 64 Products under Development by Companies, H2 2016 (Contd..10) 65 Products under Development by Companies, H2 2016 (Contd..11) 66 Products under Investigation by Universities/Institutes, H2 2016 67 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 68 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 69 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 70 Obesity - Pipeline by Abeome Corporation, H2 2016 71 Obesity - Pipeline by Acylin Therapeutics Inc, H2 2016 72 Obesity - Pipeline by Advinus Therapeutics Ltd, H2 2016 73 Obesity - Pipeline by Aegis Therapeutics, LLC, H2 2016 74 Obesity - Pipeline by Akron Molecules AG, H2 2016 75 Obesity - Pipeline by Alize Pharma SAS, H2 2016 76 Obesity - Pipeline by Amabiotics SAS, H2 2016 77 Obesity - Pipeline by Amgen Inc., H2 2016 78 Obesity - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2016 79 Obesity - Pipeline by Arena Pharmaceuticals, Inc., H2 2016 80 Obesity - Pipeline by AstraZeneca Plc, H2 2016 81 Obesity - Pipeline by Asubio Pharma Co., Ltd., H2 2016 82 Obesity - Pipeline by Athersys, Inc., H2 2016 83 Obesity - Pipeline by Biophytis SAS, H2 2016 84 Obesity - Pipeline by BioRestorative Therapies, Inc., H2 2016 85 Obesity - Pipeline by Boehringer Ingelheim GmbH, H2 2016 86 Obesity - Pipeline by Braasch Biotech LLC, H2 2016 87 Obesity - Pipeline by C3 Jian, Inc, H2 2016 88 Obesity - Pipeline by Carmot Therapeutics Inc, H2 2016 89 Obesity - Pipeline by Chronos Therapeutics Limited, H2 2016 90 Obesity - Pipeline by CohBar, Inc., H2 2016 91 Obesity - Pipeline by CoMentis, Inc., H2 2016 92 Obesity - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 93 Obesity - Pipeline by Corium International, Inc., H2 2016 94 Obesity - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 95 Obesity - Pipeline by Diabetica Limited, H2 2016 96 Obesity - Pipeline by DiscoveryBiomed, Inc., H2 2016 97 Obesity - Pipeline by Eli Lilly and Company, H2 2016 98 Obesity - Pipeline by Esperion Therapeutics, Inc., H2 2016 99 Obesity - Pipeline by Eternygen GmbH, H2 2016 100 Obesity - Pipeline by Evotec AG, H2 2016 101 Obesity - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 102 Obesity - Pipeline by FibroGen Inc, H2 2016 103 Obesity - Pipeline by Galenea Corp., H2 2016 104 Obesity - Pipeline by Gila Therapeutics Inc, H2 2016 105 Obesity - Pipeline by Gilead Sciences, Inc., H2 2016 106 Obesity - Pipeline by GlaxoSmithKline Plc, H2 2016 107 Obesity - Pipeline by GTx, Inc., H2 2016 108 Obesity - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 109 Obesity - Pipeline by Handok Inc., H2 2016 110 Obesity - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 111 Obesity - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 112 Obesity - Pipeline by Immungenetics AG, H2 2016 113 Obesity - Pipeline by Intarcia Therapeutics, Inc., H2 2016 114 Obesity - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 115 Obesity - Pipeline by Ixchel Pharma, LLC, H2 2016 116 Obesity - Pipeline by Jenrin Discovery, Inc., H2 2016 117 ity - Pipeline by Johnson & Johnson, H2 2016 118 Obesity - Pipeline by Lead Discovery Center GmbH, H2 2016 120 Obesity - Pipeline by Leading BioSciences, Inc., H2 2016 121 Obesity - Pipeline by LEO Pharma A/S, H2 2016 122 Obesity - Pipeline by LG Life Science LTD., H2 2016 123 Obesity - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016 124 Obesity - Pipeline by M Pharmaceutical Inc., H2 2016 125 Obesity - Pipeline by Magnus Life Ltd, H2 2016 126 Obesity - Pipeline by MAKScientific, LLC, H2 2016 127 Obesity - Pipeline by MedImmune LLC, H2 2016 128 Obesity - Pipeline by Merck & Co., Inc., H2 2016 129 Obesity - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016 130 Obesity - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 131 Obesity - Pipeline by NeuroNano Pharma Inc, H2 2016 132 Obesity - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016 133 Obesity - Pipeline by NIBEC, H2 2016 134 Obesity - Pipeline by Nordic Bioscience A/S, H2 2016 135 Obesity - Pipeline by Novo Nordisk A/S, H2 2016 136 Obesity - Pipeline by ObeTherapy Biotechnology, H2 2016 137 Obesity - Pipeline by Ogeda SA, H2 2016 138 Obesity - Pipeline by Omeros Corporation, H2 2016 139 Obesity - Pipeline by OPKO Biologics Ltd, H2 2016 140 Obesity - Pipeline by OPKO Health, Inc., H2 2016 141 Obesity - Pipeline by Orbis Biosciences Inc, H2 2016 142 Obesity - Pipeline by Orexigen Therapeutics, Inc., H2 2016 143 Obesity - Pipeline by Pfizer Inc., H2 2016 144 Obesity - Pipeline by PharmaIN Corporation, H2 2016 145 Obesity - Pipeline by Poxel SA, H2 2016 146 Obesity - Pipeline by Progenra, Inc., H2 2016 147 Obesity - Pipeline by Prometheon Pharma, LLC, H2 2016 148 Obesity - Pipeline by ReCyte Therapeutics, Inc., H2 2016 149 Obesity - Pipeline by Renova Therapeutics Inc, H2 2016 150 Obesity - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 151 Obesity - Pipeline by Saniona AB, H2 2016 152 Obesity - Pipeline by Sanofi, H2 2016 153 Obesity - Pipeline by Selvita S.A., H2 2016 154 Obesity - Pipeline by Seoul Pharma Co., Ltd., H2 2016 155 Obesity - Pipeline by Shionogi & Co., Ltd., H2 2016 156 - Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2016 157 Obesity - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 159 Obesity - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 160 Obesity - Pipeline by Toray Industries, Inc., H2 2016 161 Obesity - Pipeline by Umecrine AB, H2 2016 162 Obesity - Pipeline by Vicore Pharma AB, H2 2016 163 Obesity - Pipeline by Viking Therapeutics, Inc., H2 2016 164 Obesity - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016 165 Obesity - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016 166 Obesity - Pipeline by XL-protein GmbH, H2 2016 167 Obesity - Pipeline by Yuyu Pharma, Inc., H2 2016 168 1`Obesity - Pipeline by Zafgen Inc., H2 2016 169 Obesity - Pipeline by Zealand Pharma A/S, H2 2016 170 Assessment by Monotherapy Products, H2 2016 171 Assessment by Combination Products, H2 2016 172 Number of Products by Stage and Target, H2 2016 174 Number of Products by Stage and Mechanism of Action, H2 2016 182 Number of Products by Stage and Route of Administration, H2 2016 190 Number of Products by Stage and Molecule Type, H2 2016 192 Obesity - Dormant Projects, H2 2016 495 Obesity - Dormant Projects (Contd..1), H2 2016 496 Obesity - Dormant Projects (Contd..2), H2 2016 497 Obesity - Dormant Projects (Contd..3), H2 2016 498 Obesity - Dormant Projects (Contd..4), H2 2016 499 Obesity - Dormant Projects (Contd..5), H2 2016 500 Obesity - Dormant Projects (Contd..6), H2 2016 501 Obesity - Dormant Projects (Contd..7), H2 2016 502 Obesity - Dormant Projects (Contd..8), H2 2016 503 Obesity - Dormant Projects (Contd..9), H2 2016 504 Obesity - Dormant Projects (Contd..10), H2 2016 505 Obesity - Dormant Projects (Contd..11), H2 2016 506 Obesity - Dormant Projects (Contd..12), H2 2016 507 Obesity - Dormant Projects (Contd..13), H2 2016 508 Obesity - Dormant Projects (Contd..14), H2 2016 509 Obesity - Dormant Projects (Contd..15), H2 2016 510 Obesity - Dormant Projects (Contd..16), H2 2016 511 Obesity - Dormant Projects (Contd..17), H2 2016 512 Obesity - Dormant Projects (Contd..18), H2 2016 513 Obesity - Dormant Projects (Contd..19), H2 2016 514 Obesity - Dormant Projects (Contd..20), H2 2016 515 Obesity - Dormant Projects (Contd..21), H2 2016 516 Obesity - Dormant Projects (Contd..22), H2 2016 517 Obesity - Dormant Projects (Contd..23), H2 2016 518 Obesity - Dormant Projects (Contd..24), H2 2016 519 Obesity - Discontinued Products, H2 2016 520 Obesity - Discontinued Products (Contd..1), H2 2016 521 Obesity - Discontinued Products (Contd..2), H2 2016 522 Obesity - Discontinued Products (Contd..3), H2 2016 523 Obesity - Discontinued Products (Contd..4), H2 2016 524 Obesity - Discontinued Products (Contd..5), H2 2016 525 Obesity - Discontinued Products (Contd..6), H2 2016 526
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
